Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice

Sohji Nishina(Kawasaki Medical School), Keisuke Hino(Yamaguchi University), Kohei Kaku(Kurashiki Medical Center), Kyo Sasaki(Kawasaki Medical School), Futoshi Kuribayashi(Kawasaki Medical School), Akira Yamauchi(National Defense Medical College), Takumi Kawaguchi(Kurume University), Yasuyuki Tomiyama, Moritaka Goto(Riso Kagaku (Japan)), Yuichi Hara(Osaka Institute of Technology), Takuji Torimura(Omuta hospital)
Cellular and Molecular Gastroenterology and Hepatology
September 11, 2018
10.1016/j.jcmgh.2018.08.008
Cited by 101

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations
|Nature Genetics|2008|728
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536